- Immunogenics: Immunostimulatory Oligodeoxynucleotides from Probiotics

Probiotics ◽  
2013 ◽  
pp. 347-364
Keyword(s):  
Immunostimulatory Oligodeoxynucleotides

scholarly journals Preinfection Treatment of Resistant Mice with CpG Oligodeoxynucleotides Renders Them Susceptible to Friend Retrovirus-Induced Leukemia

2003 ◽  
Vol 77 (19) ◽  
pp. 10658-10662 ◽  
Author(s):  
Anke R. M. Olbrich ◽  
Simone Schimmer ◽  
Ulf Dittmer
Keyword(s):  
Viral Infections ◽  
Critical Factor ◽  
Target Cells ◽  
Cpg Odn ◽  
Friend Virus ◽  
Erythroid Precursor ◽  
Viral Loads ◽  
Cpg Oligodeoxynucleotides ◽  
Friend Retrovirus ◽  
Immunostimulatory Oligodeoxynucleotides

ABSTRACT We recently reported that immunostimulatory oligodeoxynucleotides (CpG oligodeoxynucleotides [CpG-ODN]) were effective in postexposure treatment of retrovirus-induced disease (A. R. M. Olbrich et al., J. Virol. 76:11397-11404, 2002). We now show that the timing of treatment is a critical factor in treatment efficacy. In stark contrast to the success of postexposure treatments, we found that CpG treatment of susceptible mice prior to Friend retrovirus infection accelerated the development of virus-induced erythroleukemia. Furthermore, 70.8% of mice that were resistant to Friend virus-induced leukemia developed disease after inoculation of CpG-ODN before infection. The CpG pretreatment of these mice enhanced viral loads in their spleens and blood compared to controls that received ODN without CpG motifs. The main target cells of Friend virus, erythroid precursor cells and B cells, proliferated after CpG-ODN inoculation and provided an enlarged target cell population for viral infection. Our present findings together with our previous report demonstrate that CpG-ODN treatment of viral infections may be a double-edged sword that can result in an effective therapy but also in an acceleration of disease progression depending on the time point of treatment.

scholarly journals Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses

Blood ◽  
2009 ◽  
Vol 114 (12) ◽  
pp. 2459-2466 ◽  
Author(s):  
Alix E. Seif ◽  
David M. Barrett ◽  
Michael Milone ◽  
Valerie I. Brown ◽  
Stephan A. Grupp ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Cpg Odn ◽  
Immune Therapies ◽  
Immunostimulatory Oligodeoxynucleotides ◽  
Minimal Residual

AbstractAcute lymphoblastic leukemia (ALL) is the most common childhood cancer and remains a major cause of mortality in children with recurrent disease and in adults. Despite observed graft-versus-leukemia effects after stem cell transplantation, successful immune therapies for ALL have proven elusive. We previously reported immunostimulatory oligodeoxynucleotides containing CpG motifs (CpG ODN) enhance allogeneic Th1 responses and reduce leukemic burden of primary human ALL xenografts. To further the development of CpG ODN as a novel ALL therapy, we investigated the antileukemia activity induced by CpG ODN in a transplantable syngeneic pre-B ALL model. CpG ODN induced early killing of leukemia by innate immune effectors both in vitro and in vivo. Mice were treated with CpG ODN starting 7 days after injection with leukemia to mimic a minimal residual disease state and achieved T cell–dependent remissions of more than 6 months. In addition, mice in remission after CpG ODN treatment were protected from leukemia rechallenge, and adoptive transfer of T cells from mice in remission conferred protection against leukemia growth. To our knowledge, this is the first demonstration that CpG ODN induce a durable remission and ongoing immune-mediated protection in ALL, suggesting this treatment may have clinical utility in patients with minimal residual disease.

Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen

Vaccine ◽  
2004 ◽  
Vol 22 (23-24) ◽  
pp. 3053-3060 ◽  
Author(s):  
Poonam Tewary ◽  
Bindu Sukumaran ◽  
Shailendra Saxena ◽  
Rentala Madhubala
Keyword(s):  
Protective Immunity ◽  
Immunostimulatory Oligodeoxynucleotides
Sign in / Sign up

Export Citation Format

Share Document